来自来世的回归? 针对晚期KRAS突变肺癌的索托拉西布治疗:一个病例报告

Ming-Xing Wang1, Pei Zhu1, Yue Shi2

  • 1Department of Medical Oncology, Lu'an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu'an 237000, Anhui Province, China.

PubMed
概括

索托拉西布有效治疗具有KRAS G12C突变的晚期非小细胞肺癌 (NSCLC). 向治疗显示显著的临床改善,没有观察到有毒副作用.